Category: Biotechnology

Valentis Licenses Geneswitch Technology To Wyeth-Ayers

Valentis, Inc. has granted a non-exclusive license of the Company’s GeneSwitch gene regulation technology to Wyeth-Ayerst Laboratories. The GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, aiding in the identification and characterization of a gene’s function. Valentis is currently developing the GeneSwitch system as Read more about Valentis Licenses Geneswitch Technology To Wyeth-Ayers[…]

Biopulse Acquires Cancer Vaccine

BioPulse International, Inc. has acquired a new and improved method of creating dendritic cell cancer vaccines. “Antigens associated with cancerous tumours are not normally recognized by the immune system. With dendritic cell therapy, we’re teaching the dendritic cells to recognize the cancer antigens,” explains Dr. Robert Morrow, Director of Clinical Research for BioPulse. If the Read more about Biopulse Acquires Cancer Vaccine[…]

Coulter And Cobra Agree Collaboration

Coulter Pharmaceutical, Inc. and Cobra Therapeutics Ltd, the gene therapy subsidiary of ML Laboratories, have entered into a collaboration to jointly develop and commercialise Cobra’s platform gene expression technology. The technology, known as Ubiquitous Chromatin Opening Elements (UCOEs), is a new class of gene expression elements which induce efficient productivity from genes introduced into target Read more about Coulter And Cobra Agree Collaboration[…]

AME Signs Licensing Agreement With IDEXX For Diagnostic Development

Applied Molecular Evolution, Inc., has granted a non-exclusive sublicense to IDEXX Laboratories, Inc., for Applied Molecular Evolution’s (AME’s) Kauffman patents for directed evolution. IDEXX plans to use the Kauffman patents to develop diagnostic applications. “We believe that IDEXX’ decision to take this license reflects the value of our proprietary position in the field of directed Read more about AME Signs Licensing Agreement With IDEXX For Diagnostic Development[…]

eli lilly

Lilly And Ceptyr Announce Drug Discovery Collaboration

Eli Lilly and Company and Ceptyr, Inc., have announced a two-year research collaboration for the discovery of small molecules to treat diabetes, obesity, and impaired glucose tolerance. The collaboration will focus on the phosphatase target, PTP1B, using Ceptyr’s proprietary assays and screening technology. Ceptyr will receive an upfront signing fee, research funding, milestone payments and Read more about Lilly And Ceptyr Announce Drug Discovery Collaboration[…]

lexicon genetics incorporated

Lexicon Sub-licenses Knockout Mouse Technology

Lexicon Genetics Incorporated has granted a non-exclusive sublicense to Biogen, Inc. for the use of certain aspects of Lexicon’s positive- negative selection technology for the generation of knockout mice. Biogen will use the technology in its internal drug-discovery and target validation programs. Financial terms were not disclosed. Lexicon‘s positive-negative selection technology is one of the Read more about Lexicon Sub-licenses Knockout Mouse Technology[…]

Diversa Expands Patent Protection Of Drug Screening Technologies

Diversa Corporation has been issued U.S. Patent No. 6,057,103 expanding its proprietary position for identifying and optimizing biologically active molecules derived from its compound libraries. The patent covers methods for producing and derivatizing small molecules that may be effective as antibiotics, anti-virals, anti-tumor agents and regulatory proteins. The method also encompasses capturing genes and gene Read more about Diversa Expands Patent Protection Of Drug Screening Technologies[…]

Progenics And Cytogen Announce Progress On Vaccine And Antibody Therapies For Prostate Cancer

Progenics Pharmaceuticals, Inc. and Cytogen Corporation have announced new findings on immune therapies which may play a future role in the treatment of prostate and other cancers. The therapies are directed against Prostate Specific Membrane Antigen (PSMA), a molecular cancer marker that is abundantly expressed on the surface of prostate cancer cells. The developments, presented Read more about Progenics And Cytogen Announce Progress On Vaccine And Antibody Therapies For Prostate Cancer[…]

Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration

CuraGen Corporation, an integrated genomics based drug discovery and development company, and Gemini Genomics plc, announced today the largest collaboration to date linking cSNPs (human genetic variations) and clinical information to identify and validate novel drug targets for use in the discovery and development of pharmaceutical and diagnostic products. Specifically, CuraGen and Gemini scientists will Read more about Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration[…]